While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

Bayer launches Felujit fungicide for paddy cultivation, offering superior protection against sheath blight with dual-action ...

DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for ...

Singapore-based market expansion services provider DKSH Business Unit Healthcare announced a partnership with Germany’s Bayer ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral neurokinin (NK) 1 and 3 antagonist, under the Lynkuet brand name, for the treatment of moderate to severe vasomotor ...

Berlin: Bayer has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA, regulatory authority ...

Bayer seeks European marketing authorization for investigational contrast agent, gadoquatrane: Berlin Friday, July 11, 2025, 11:00 Hrs [IST] Bayer announced the submission of a ma ...

The Ministry of Business and Made in Italy has awarded Bayer Italia the "Excellence of the Production System and Made in ...

Bayer receives UK MHRA approval for Lynkuet to treat moderate to severe vasomotor symptoms associated with menopause: Berlin Saturday, July 12, 2025, 10:00 Hrs [IST] Bayer announc ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Bayer Schering Pharma, headquartered in Berlin, now operates together with Bayer’s existing Pharmaceuticals business as a division of the Bayer HealthCare subgroup.

Bayer Crop Science is closing its Hastings research site. The 2019 NZIER report estimates New Zealand’s economy would lose ...